Drugs that contain Tofacitinib Citrate
1. List of Xeljanz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(8 days ago) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 14, 2024 |
| New Patient Population (NPP) | Sep 25, 2023 |
Market Authorisation Date: 06 November, 2012
Treatment: NA
Dosage: TABLET;ORAL
XELJANZ family patents
3
United States
1
South Africa
1
Denmark
1
IB
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Uruguay
1
Norway
1
Germany
1
Argentina
1
Colombia
1
Brazil
1
Honduras
1
Guatemala
1
Cyprus
1
Spain
1
Peru
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
China
1
Japan
1
Canada
1
Panama
1
New Zealand
1
European Union
2. List of Xeljanz drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 25, 2023 |
Market Authorisation Date: 25 September, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
3. List of Xeljanz Xr drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PFIZER | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(8 days ago) | |
| USRE41783 | PFIZER | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
| US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 14, 2024 |
Market Authorisation Date: 23 February, 2016
Treatment: A method of treating ankylosing spondylitis by administering the formulation of tofacitinib of claims 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, and 87-98; A method o...
Dosage: TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR family patents
11
United States
6
Korea, Republic of
4
Japan
3
Israel
3
South Africa
3
Australia
3
Russia
3
China
3
Canada
3
New Zealand
3
European Union
2
Denmark
2
IB
2
Mexico
2
Hong Kong
2
Argentina
2
Brazil
2
Singapore
2
Spain
2
Poland
2
Taiwan, Province of China
1
Austria
1
Slovenia
1
Hungary
1
Uruguay
1
Norway
1
Germany
1
Colombia
1
Honduras
1
Portugal
1
Guatemala
1
Cyprus
1
Peru
1
Panama
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic